FIELD MAP / TUMOR TYPE

Ovarian cancer

Ovarian cancer — a setting for neoantigen and shared-antigen vaccine strategies.

Topic2 items2026-06-08 – 2026-06-30

Tumor types

Glioblastoma25 Melanoma23 Pancreatic cancer19 Colorectal cancer18 Lung cancer (NSCLC)17 Breast cancer11 Liver cancer (HCC)8 Kidney cancer (RCC)7 Lynch syndrome7 Head & neck cancer5 Ovarian cancer2 Gastric cancer2 Prostate cancer2 Bladder cancer1

Clinical

A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery

West China Hospital has registered a Phase I, single-arm, open-label dose-escalation study for NeoOVIV in stage II/III ovarian cancer patients post-surgery. The personalized mRNA-lipid nanoparticle vaccine will be administered with standard adjuvant chemotherapy and a PD-1 antibody to evaluate safety, tolerability, immunogenicity, and preliminary clinical activity.

clinicaltrials · brief 2026-06-30 · published 2026-06-30

Clinical

A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer

Peking University Third Hospital is preparing a not-yet-recruiting dose-escalation study for YS247, a tumor neoantigen-pulsed autologous dendritic cell injection. The trial will evaluate safety, tolerability, and preliminary efficacy in participants with HRD-negative epithelial ovarian cancer.

clinicaltrials · brief 2026-06-08 · published 2026-03-16